117 results about "Biodistribution" patented technology

The present invention provides drug delivery vehicles comprising polytheylyene-lipid conjugates (PEG-lipid), wherein the circulation lifetime and biodistribution of the drug delivery vehicles are regulated by the PEG-lipid. More particularly, the present invention provides liposomes, SNALP and SPLP comprising such PEG-lipid conjugates, and methods of using such compositions to selectively target a tumor site or other tissue of interest (e.g., liver, lung, spleen, etc.).

Cluster clearing agents (CCAs) and the use thereof are discussed. CCAs are composed of a hepatic clearance directing moiety which directs the biodistribution of a CCA-containing construct to hepatic clearance; and a binding moiety which mediates binding of the CCA to a compound for which rapid hepatic clearance is desired.

The invention provides formulations and structural modifications for phenothiazine compounds which result in altered biodistributions, thereby reducing the occurrence of adverse reactions associated with this class of drug.

The invention is directed to oligonucleotides and oligonucleosides functionalized to include lipophilic moieties and having improved biostability and altered biodistribution in mammals. In one embodiment, such lipophilic oligonucleotide conjugates are used in a method of targeting antisense oligonucleotides to hepatic tissues and thereby preferentially modulating gene expression in the liver and associated tissues of a mammal.

Degradable polyacetal polymers and functionalized degradable polyacetal polymers have properties favorable for use in pharmaceutical and biomedical applications. The degradable polyacetal polymers are relatively stable at physiological pH with favorable biodistribution profiles, and degrade readily in low pH conditions. Conjugates of the polymers with drugs, especially anticancer drugs, and methods of treatment of cancer.

The size and location of microsphere uptake/delivery are important determinants of the final biodistribution of oral microsphere systems. Formulations, kits, methods of administering the formulations, and using the kits are described herein. The formulations are oral dosage formulations. In one embodiment, the formulations contain microparticles and/or nanoparticles having a homogenous size range selected to optimize uptake in a specific region of the GI tract and target drug delivery to specific organs. In some embodiments, the dosage formulation contains an enteric coating and/or a magnetic material. In a preferred embodiment, the formulation contains a magnetic material and an active agent to be delivered, optionally the active agent is in the form of micro- or nano-particles. In some embodiments metallomucoadhesive materials and/or magnetic materials are employed as magnetic and/or mucoadhesive sources. Formulations containing magnetic materials can be localized using the kits and methods disclosed herein. In one embodiment, the method includes orally administering the formulation and applying an extracorporeal magnet to a site on the outside surface of the patient's body in an area that closely apposes the location in the gastrointestinal tract to which delivery of the formulation is desired. The extracorporeal magnet is applied for a suitable time period to allow for the drug to be released from the formulation and/or to allow for the formulation to adhere to the site. Both magnetic and mucoadhesive forces may be utilized to site-direct and retain the dosage form in the region of the gastrointestinal (GI) tract most suitable for the desired delivery.

Complexes comprising a nucleic acid molecule and a conjugated peptide nucleic acid (PNA). The PNA may be labeled or conjugated to a protein, peptide, carbohydrate moiety or receptor ligand. These complexes are used to transfect cells to monitoring plasmid biodistribution, promote nuclear localization, induce transcriptional activation, lyse the endosomal compartment and facilitate transfection. These complexes increase the efficiency of expression of a particular gene.

A method for treating a human patient is provided, including administering a radiolabeled form of a therapeutic agent to the patient at a first substantially non-therapeutically-effective dose, wherein pharmacological activity of the therapeutic agent is not due to radioactivity of the therapeutic agent. The method also includes determining information related to a biodistribution of the radiolabeled form of the therapeutic agent in the patient by performing a radioimaging procedure on the patient. Responsively to the information, a decision is made whether or not to treat the patient by administering the therapeutic agent to the patient. If the decision is made to treat the patient, the patient is treated by administering the therapeutic agent to the patient at a second therapeutically-effective dose. If the decision is made not to treat the patient, treatment of the patient with the therapeutic agent is withheld. Other embodiments are also described.

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

The invention is directed to an improved drug delivery system that includes a micelle, comprising polyethylene glycol and a lipid component, and a pharmaceutical agent dispersed in the lipid component. The delivery system may also include a targeting ligand. The micelle delivery system of the invention is capable of stabilizing, inter alia, poorly soluble pharmaceutical agents and increasing their delivery efficacy. Appropriate pharmaceutical agents useful in the system of the invention include anti-inflammatory agents, agents for photodynamic therapy, anti-tumor agents, anti-neoplastic agents, anti-metastatic agents, and imaging agents, as well as hydrophobized derivatives thereof. Specifically, the pharmaceutical agent can be porphyrin, chlorine-6-trimethyl ester, tamoxifen, paclitaxel, 1,3-bis(2-chloroethyl)-1-nitrosourea, camptothecin, ellipticine, rhodamine, dequalinium, diphenylhexatriene, vitamin K3, diethylene triamine pentaacetic acid, or a functional derivative thereof. The micelles in the system of the invention have low critical micellar concentration and high kinetic stability, which provides great advantages in biodistribution, for example, accumulation at the site of a tumor.

The DCC (Data Consistency Condition) algorithm is used in combination with MLAA (Maximum Likelihood reconstruction of Attenuation and Activity) to generate extended attenuation correction maps for nuclear medicine imaging studies. MLAA and DCC are complementary algorithms that can be used to determine the accuracy of the mu-map based on PET data. MLAA helps to estimate the mu-values based on the biodistribution of the tracer while DCC checks if the consistency conditions are met for a given mu-map. These methods are combined to get a better estimation of the mu-values. In gated MR/PET cardiac studies, the PET data is framed into multiple gates and a series of MR based mu-maps corresponding to each gate is generated. The PET data from all gates is combined. Once the extended mu-map is generated the central region is replaced with the MR based mu-map corresponding to that particular gate. On the other hand, in dynamic PET studies the uptake in the patient's arms reaches a steady state only after the tracer distributes throughout the body. Hence, for dynamic scans, the projection data of all frames is summed and used to generate the MLAA based extended mu-map for all frames.

Oxygen levels in biological tissue or systems can be measured by the phosphorescence quenching method using phosphorescent porphyrin probes, also referred to as a dendritic oxygen probes, with controllable quenching parameters and defined biodistributions. Provided are a “next generation” of oxygen sensors with substantially improved phosphorescence emission for better imaging capabilities, ease of use, increasing the quantum efficiency (phosphorescence intensity) and extending their range of applicability including constructing a class of oxygen sensors for making measurements in organic media. In addition, provided are methods for synthesizing new porphyrin constructs in which the porphyrin is made less flexible and more planar, changing with decrease internal quenching, and thereby increasing the phosphorescence emission used for oxygen sensing. Additional methods are provided for structurally modifying the dendrimer used to encapsulate the porphyrin phosphor to provide internal quenching of singlet oxygen molecules formed during oxygen measurements.

A system and method for planning a necrosis-inducing therapy and subsequent administration of a necrosis-targeting agent are described. The system takes into account the effect of necrosis-induction therapy as a basis for the biodistribution estimate of the necrosis-targeting agent. This interaction between the different calculation steps is essential for an accurate planning result. A computer-readable medium and use are also provided.

An echo-scintigraphic probe for medical applications and the method of merging images. It is constituted by the union of an ultrasound probe suitably integrated, both in geometric terms, and in terms of image processing, with a scintigraphic probe or gamma camera (3). With a single application of said probe, one is able to provide a double image of the object under examination. The ultrasound probe is housed in the head, above the plane of the collimator and kept projecting to favor the direct contact with the body part of the patient to be examined. The collimator is able to obtain images of the biodistribution of a radiolabelled drug by radiation with frontal incidence, maintaining the characteristics of the ultrasound probe. The probe is applicable to both clinical diagnosis and intraoperative diagnosis of cancer with the use of radio tracers. A guided diagnostic method is disclosed that realizes a functional integration of a pair of ultrasound and scintigraphic images concurrently obtained by the echo-scintigraphic probe.

A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.

The quantitative evaluation of biomarker-probe activity is disclosed. In certain embodiments, the biomarker-probe activity may be quantified and analyzed using biodistributions generated using a model. In some embodiments, such biodistributions may be used to generate simulated images from which quantitative thresholds may be derived. In some embodiments, the quantitative thresholds may be used to analyze the biodistributions.

The invention discloses novel radioactive 18F labeled amino acid derivatives, which are used in research on tumor positron emission tomography (PET) imaging. The derivatives are characterized in that one end of the derivatives is provided with F substituted alkoxy benzoyl structure, and the other end of the derivatives is provided with alpha-amino acid structure; substituent R1 is positioned on an alpha site of carboxyl group and is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; R2 is methoxy group; and n is a number between 1 and 5. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is hydrogen; and the n is a number between 1 and 5. Compounds improve fat solubility. Different amino acid structures are introduced into the structure, and F in the structure is 19F and 18F. Compared with the prior art, the 18F labeled amino acid derivatives provided by the invention have better discrimination degree of biological distribution, the potential of being used as a tumor imaging agent (particularly a brain tumor imaging agent), as well as the characteristics of simple preparation and high labeling rate. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is methoxy group; and the n is a number between 1 and 5. The R1 is hydrogen, methyl group, ethyl group, propyl group, isopropyl group, butyl group, methylthio-ethyl group, methyl acetate group or propionate carbomethoxy group; the R2 is hydrogen; and the n is a number between 1 and 5.

The invention discloses an antibody-polymer combined body and a fluorescent derivative thereof and a preparation method of the antibody-polymer combined body and the fluorescent derivative. The antibody comprises at least one disulfide bond or free sulfydryl; the polymer is combined to the antibody through connection to the disulfide bond or free sulfydryl of the antibody; according to the method, a specific site of the antibody is modified; a polymer and a fluorescent derivative thereof grow in situ; or a polymer and a fluorescent derivative thereof are prepared in advance; and the antibody-polymer combined body and the fluorescent derivative thereof are prepared in a manner of specific site coupling of the antibody. The method disclosed by the invention is simple, convenient and efficient; the prepared product not only reserves the original biological activity of the antibody, but also improves the water solubility, stability, pharmacokinetics, distribution of organisms and treatment efficacy; the immunogenicity is reduced; in addition, compared with an antibody-fluorescence indicator prepared by the traditional method, the antibody-polymer fluorescent derivative prepared by the method has stronger fluorescence signal and detection signal strength.

The invention discloses a nano-micelle. The nano-micelle comprises an AIE (aggregation-induced emission) dye, an active pharmaceutical ingredient and an amphipathic carrier in a mass ratio of 1 to 1 to (5-10). The invention further discloses a preparation method of the nano-micelle and application of the nano-micelle in preparing tumor diagnosing and/or treating agents. The nano-micelle is capable of realizing integration of diagnosis and treatment, is used for in-vivo non-invasive fluorescence imaging, diagnosis and disease treatment, and can be well gathered on a tumor site by sufficiently utilizing the EPR effect of a tumor, so that the active pharmaceutical ingredient carried by the nano-micelle can be enriched on the tumor site to play a role in effectively treating the tumor; furthermore, an AIE red-light dye is high in luminous efficiency, is not easy to quench, is capable of well reflecting the situation of delivery and biological distribution of the active pharmaceutical ingredient in a body, and can be used for diagnosing tumors.

The invention discloses a method for detecting human DNA by specifically detecting the human SRGAP2 gene, a primer and probe for specifically detecting the human SRGAP2 gene, and a TaqMan qPCR methodcapable of being used for detecting the human DNA in animal organs, tissue, cells, body fluid and blood. The method is suitable for detecting the human DNA in any animal sample and includes but not limited to biochores, metabolism and residues of cell and gene treatment products in the body of an animal receiving treatment.